• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Consumer Skin Devices Are Growing Fast. The Evidence Is Still Catching Up.

by HITC Staff 11/17/2026 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

The line between a medical procedure and a consumer product has been moving for years. Blood pressure cuffs, glucose monitors and heart rhythm sensors now sit in ordinary households. Skincare is following a similar path, and it raises familiar questions about evidence, regulation and data.

Few categories show this more clearly than at-home micro infusion. Devices sold as the best micro infusion system for home use now reach hundreds of thousands of buyers, and the way their results are measured looks very different from what a hospital purchasing committee would ask for.

From clinic to consumer

Microneedling began as an in-office procedure, performed by clinicians with longer needles and supported by a body of clinical research, much of it on acne scars, though many of the studies are small.

Consumer devices took the idea in a different direction. They use much shorter needles, are designed for self-use and focus on what manufacturers call micro infusion: helping a serum absorb better than it would from the surface alone. They are cosmetic products, not procedures.

Seranova, an at-home skincare company, illustrates how the category has developed. Its system pairs a stamping device with sterile, single-use needle heads and a peptide and hyaluronic acid serum. The company reports more than one million units sold and more than 500,000 customers.

A regulatory gray zone

In the United States, the regulatory status of needle devices depends heavily on how a device is designed and marketed. Products intended to treat scars or wrinkles can fall under the Food and Drug Administration’s device oversight. Products positioned as cosmetic, focused on product absorption or appearance, often do not go through the same review.

That distinction matters for how claims are made. Seranova, like many companies in the space, states that its products have not been evaluated by the F.D.A. and are not intended to diagnose, treat, cure or prevent any disease. Its claims are framed around appearance: skin that looks firmer, smoother or more even.

For health technology observers, this is a familiar pattern. Consumer products can reach the market faster and at lower cost than regulated medical devices, and the type of evidence behind them is often different.

How companies measure results

The data that consumer skincare companies publish tends to fall into three categories.

The first is safety and tolerance testing. Seranova cites dermatological testing in two studies of 30 subjects each to support skin compatibility. Studies of this kind are standard in the industry and are designed to detect irritation.

The second is clinical testing over a longer period. Seranova cites a 12-week study of 29 participants, conducted by EpiDermLab, an independent laboratory in Kraków, Poland. The company reports that 93 percent of participants had visibly firmer-looking skin, 72 percent a reduced appearance of wrinkles and 66 percent visibly smoother skin, with tolerance rated excellent and no adverse events. The company itself notes that the sample is small and that the study was not placebo-controlled, which is typical of cosmetic testing. Full reports, it says, are available on request.

The third is customer-reported outcomes. In a January 2026 survey of 281 Seranova customers who had purchased more than once, 80 percent said their skin appeared firmer, 78 percent said it looked younger and 87 percent said no recovery time was needed. The company discloses that these results are self-reported and not independently verified. Results vary.

That level of disclosure is worth noting. It is also a reminder of what each type of data can and cannot show. Repeat buyers are a self-selected group, and perceived improvement is a different measure from an instrument reading in a study.

An opportunity for better evidence

The challenge is not unique to skincare. Across consumer health, companies hold large amounts of user data that are rarely analyzed in ways that would satisfy a clinical reviewer. Standardized photography, validated outcome scales and independent analysis could turn customer feedback into something closer to real-world evidence.

Several features of products like Seranova’s already make that more feasible. Single-use heads and fixed session intervals, one session every two weeks, create a consistent protocol. A 90-day guarantee that asks customers to document progress with monthly photos generates structured before-and-after images.

What buyers should weigh

For now, consumers are left to evaluate claims on their own. Practical signals include sterile, single-use components, transparent ingredient lists, clear contraindications, published study information and refund policies that let users test results without a large financial risk.

Seranova points to its sterile heads, its 90-day guarantee and industry awards from beauty publications. How the category as a whole develops will depend on the next step: data that is collected and analyzed with the same rigor that health technology increasingly expects elsewhere.

The devices have already moved into the home. The evidence around them is still growing.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |